ArticleDrug design, development and therapy2026
R-α-Lipoic Acid Attenuates Acetaminophen-Induced Acute Liver Injury by Reducing Oxidative Stress, Inflammation, and Mitochondrial Damage in Mice.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acetaminophen (APAP) overdose is a leading cause of acute liver injury and is frequently associated with oxidative stress, mitochondrial dysfunction, inflammation, and hepatocellular toxicity. R-α-lipoic acid (R-ALA) is a natural antioxidant and mitochondrial cofactor that provides protective effects against APAP-induced hepatic damage. Objective: To examine the protective effects of R-ALA against acute APAP-induced liver injury in mice. Methods: Adult male mice were randomly divided into five groups: control, APAP, R-ALA, repeated R-ALA pretreatment + APAP, and single R-ALA pretreatment + APAP. APAP was given orally at 500 mg/kg, while R-ALA was administered orally at 100 mg/kg. R-ALA was administered daily for 10 days, with a single dose given 1 hour before APAP. Twenty-four hours after APAP administration, blood and liver samples were collected. Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamate dehydrogenase (GLDH), high mobility group box-1 (HMGB1), keratin-18 (K18), caspase-cleaved keratin-18 (ccK18), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were measured. Liver malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase 3 (GPx3) were also assessed. Results: APAP administration increased serum markers of hepatocellular injury, mitochondrial injury, hepatocyte death, and inflammation, including ALT, AST, GLDH, HMGB1, K18, ccK18, IL-6, and TNF-α. APAP also increased hepatic MDA and decreased hepatic GSH, SOD, CAT, and GPx3. R-ALA pretreatment significantly attenuated these APAP-induced changes. APAP increased ALT from 7.49 to 29.46 and AST from 11.10 to 32.49, while R-ALA pretreatment significantly reduced both markers compared with the APAP group. Conclusion: R-ALA attenuated APAP-induced liver injury biomarker changes in mice, through antioxidant defenses and reduction of oxidative stress, inflammatory responses, mitochondrial injury markers, and hepatocyte death markers. These protective effects are mediated by antioxidant, anti-inflammatory, and mitochondrial-protective mechanisms. Further histological and pathway-focused molecular studies are needed to confirm the underlying mechanisms and translational relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.